preloader icon

Apex Trader Funding (ATF) - News

The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly

For Immediate Release Chicago, IL – June 21, 2024 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Eli Lilly and Co. (NYSE: LLY). Here are highlights from Thursday's Analyst Blog: Here's Why Eli Lilly Is Probably the Best Drug Stock in the World Right Now Stocks of pharma companies, particularly large ones, make excellent defensive investments in an uncertain economy. Some popular names in the pharma sector are Pfizer, Johnson & Johnson, Merck, AbbVie, Novartis and Eli Lilly and Co., among others. Of these, at present, Eli Lilly appears to be a great stock to have in one's portfolio based on its strong overall financial performance and robust drug pipeline. Lilly, with a market cap of more than $800 billion, boasts a diversified product profile, including a solid lineup of new successful drugs. The company focuses primarily on diabetes, neuroscience, oncology and immunology, which are all high-growth areas and represent significant commercial potential. In the past couple of years, the company has received approvals for several new drugs and witnessed pipeline and regulatory success. The company has consistently reported strong revenues and profits and dealt well with expiring patents and increasing competition. New Drugs Hold Key to Top-Line Growth Lilly hit the jackpot with tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), which is marketed as Mounjaro for type II diabetes and Zepbound for obesity. The GLP-1 segment is a very important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks. Mounjaro was launched in mid-2022 while Zepbound was launched in November 2023. Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly, with demand ...